Dr, Ghabril is a Hepatologist at Indiana University. He has a clinical and research interest in drug-induced liver injury, and is an investigator in the Drug-Induced Liver Injury Network. He is the Program Director of the Transplant Hepatology Fellowship at IUSM, and Director of the Liver Inpatient Service at Indiana University Hospital.

Dr. Erica Johnson, board-certified in internal medicine and infectious disease, joined ABIM as its Senior Vice President for Academic and Medical Affairs in October 2024. Prior to this role, she served as the Program Director for the Internal Medicine Residency at Johns Hopkins Bayview Medical Center and Associate Vice Chair for Diversity, Equity and Inclusion in Medical Education for the Johns Hopkins Department of Medicine in Baltimore, Maryland. She remains on faculty at Johns Hopkins as Associate Professor of Medicine (part time) in the Division of Infectious Diseases.

Lisa Catalli is a Nurse Practitioner in the Hepatology Department at the University of California San Francisco and an assistant clinical professor at the UCSF School of Nursing. She holds a Master of Science degree and is currently pursuing a PhD at the UCSF School of Nursing. With over 15 years of experience in Hepatology, Lisa specializes in viral hepatitis and MASLD across the liver disease spectrum, including care for liver transplant recipients.

Whitney Steinmetz is a board-certified family nurse practitioner who provides patient-focused, evidence-based care in gastroenterology and hepatology. She has a passion for improving access to care in rural healthcare environments. Dr. Steinmetz earned her bachelor's of science degree with honors, Magna Cum Laude, at the University of Arizona.

My name is Anna Marie Hefner, PhD, RN, CPNP, FAASLD.. Her dissertation is entitled "A Descriptive Study of Nutritional Parameters in Patients with Cirrhosis. She is the Director of Nashville at a community-based liver center. We acknowledge each patient and work with the guidelines set forth with AASLD and the individual goals of the patient. We discussed their plan of action and meet them where they are at using the "HALO" approach-health and liver optimization. <br>I am a fellow of the ASSLD.

Ms. Zapatka, MSN, APN-BC is currently the VA CT Healthcare System's (VACHS) Liver Resource Center's Nurse Practitioner. Susan was the NP Co-Director for the Center of Excellence in Primary Care Education, and recipient of many nursing and academic awards, including Yale School of Medicine Internal Medicine Primary Care Residency Program – Support Staff Recognition Award and the CTAPRN NP of the Year Award.

Dr. Fenkel is a Professor of Medicine at Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia, PA, USA. He is the Director of the Jefferson Viral Hepatitis Center and Associate Medical Director of Liver Transplantation at Thomas Jefferson University Hospital.

I am a Professor of Medicine and Transplant Hepatologist at UCSF. My NIH-funded research focuses on the intersections of HIV, viral hepatitis, and hepatic steatosis.

As a hepatologist and Associate Director in CDER's Office of Pharmacovigilance and Epidemiology, Dr. Avigan has served as an expert consultant at FDA for the evaluation of drug-induced liver injury during the life cycle of drugs and biological agents. Earlier on, Dr. Avigan received his MD from McGill University. After his medical residency and GI fellowship, he trained as an NIH staff fellow and then was on the faculty of Georgetown University where he attended patients and was the principal investigator of NIH-funded grants to elucidate basic mechanisms in cell growth pathways.

Eric Cohen, MD is a Senior Medical Director in Pharmacovigilance at Abbvie Inc. and serves as the Chair of the Liver Internal Safety Advisory Group (ISAG). Dr. Cohen completed his fellowship training in Gastroenterology & Hepatology at Yale New Haven Medical Center (2009) and an advanced fellowship in Transplant Hepatology at Beth Israel Deaconess Medical Center (2010). He is an active member of IQ-DILI and is a key opinion leader in the field of hepatotoxicity.